Market News

EPS for Cancer Genetics, Inc. (CGIX) Expected At $-0.08; 4 Analysts Covering Union Bankshares (UBSH)

Union Bankshares Corporation (NASDAQ:UBSH) Logo

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.08 EPS on May, 10.They anticipate $0.03 EPS change or 27.27% from last quarter’s $-0.11 EPS. After having $-0.35 EPS previously, Cancer Genetics, Inc.’s analysts see -77.14% EPS growth. The stock decreased 3.99% or $0.0534 during the last trading session, reaching $1.2866. About 2.59 million shares traded or 329.27% up from the average. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 66.34% since April 17, 2017 and is downtrending. It has underperformed by 77.89% the S&P500.

Among 9 analysts covering Union First Market Bankshares Corporation (NASDAQ:UBSH), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Union First Market Bankshares Corporation had 37 analyst reports since July 22, 2015 according to SRatingsIntel. Brean Capital initiated Union Bankshares Corporation (NASDAQ:UBSH) on Wednesday, November 30 with “Hold” rating. As per Tuesday, December 12, the company rating was maintained by Keefe Bruyette & Woods. The company was maintained on Monday, April 16 by Brean Capital. Raymond James maintained Union Bankshares Corporation (NASDAQ:UBSH) on Tuesday, December 12 with “Buy” rating. The rating was upgraded by Zacks on Tuesday, August 18 to “Sell”. The stock of Union Bankshares Corporation (NASDAQ:UBSH) earned “Hold” rating by Brean Capital on Wednesday, August 2. The stock of Union Bankshares Corporation (NASDAQ:UBSH) earned “Neutral” rating by Robert W. Baird on Thursday, April 21. Robert W. Baird maintained the stock with “Hold” rating in Wednesday, January 24 report. The firm has “Hold” rating given on Monday, February 5 by Brean Capital. On Tuesday, May 23 the stock rating was upgraded by Wood to “Outperform”. See Union Bankshares Corporation (NASDAQ:UBSH) latest ratings:

16/04/2018 Broker: Brean Capital Rating: Hold Maintain
05/04/2018 Broker: Brean Capital Rating: Hold Maintain
26/02/2018 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $44.0 Maintain
05/02/2018 Broker: Brean Capital Rating: Hold Maintain
29/01/2018 Broker: Brean Capital Rating: Hold Maintain
24/01/2018 Broker: Sandler O’Neill Rating: Hold New Target: $40.0 Maintain
24/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $41.0 Maintain
23/01/2018 Broker: Brean Capital Rating: Hold Maintain
24/01/2018 Broker: Merion Capital Old Rating: Outperform New Rating: Outperform Old Target: $45 New Target: $47 Maintain
10/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $38.0 Maintain

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Cancer Genetics had 12 analyst reports since March 11, 2016 according to SRatingsIntel. Aegis Capital maintained it with “Buy” rating and $8 target in Tuesday, March 15 report. As per Tuesday, January 16, the company rating was maintained by H.C. Wainwright. Maxim Group downgraded the shares of CGIX in report on Tuesday, April 3 to “Hold” rating. The firm earned “Buy” rating on Tuesday, February 6 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 29. As per Thursday, December 7, the company rating was initiated by Maxim Group. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, August 15 report. The firm has “Neutral” rating by Janney Capital given on Friday, March 11. Rodman & Renshaw initiated Cancer Genetics, Inc. (NASDAQ:CGIX) rating on Monday, September 26. Rodman & Renshaw has “Buy” rating and $6 target. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Buy” rating by H.C. Wainwright on Thursday, September 21.

Since December 15, 2017, it had 1 buy, and 0 insider sales for $24,339 activity. 12,200 shares were bought by ROBERTS JOHN A, worth $24,339 on Friday, December 15.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.34, from 0.57 in 2017Q3. It increased, as 4 investors sold Cancer Genetics, Inc. shares while 7 reduced holdings. 3 funds opened positions while 7 raised stakes. 2.78 million shares or 7.43% more from 2.58 million shares in 2017Q3 were reported. Hrt Ltd Liability Com holds 0.04% or 23,199 shares in its portfolio. Vanguard Grp Inc invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Royal National Bank & Trust Of Canada holds 9 shares or 0% of its portfolio. Virginia-based Thompson Davis & has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Australia-based Macquarie Gp has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Ltd holds 0% in Cancer Genetics, Inc. (NASDAQ:CGIX) or 454 shares. Morgan Stanley invested in 0% or 16,269 shares. 87,279 are owned by Geode Capital Management Limited Liability. National Bank Of America De holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 625 shares. Blackrock holds 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX) for 45,767 shares. Virtu Financial Limited Liability Corporation holds 0% in Cancer Genetics, Inc. (NASDAQ:CGIX) or 27,293 shares. Diker Management Lc, New York-based fund reported 67,055 shares. Renaissance Ltd Liability Corp accumulated 519,800 shares. Wells Fargo Mn reported 14,200 shares. Northern Trust Corporation holds 0% in Cancer Genetics, Inc. (NASDAQ:CGIX) or 32,576 shares.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $35.70 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The stock decreased 1.26% or $0.46 during the last trading session, reaching $35.97. About 158,808 shares traded. Union Bankshares Corporation (NASDAQ:UBSH) has risen 7.77% since April 17, 2017 and is uptrending. It has underperformed by 3.78% the S&P500.

Union Bankshares Corporation operates as the bank holding firm for Union Bank & Trust that provides banking and related financial services to clients and businesses. The company has market cap of $2.37 billion. The firm operates in two divisions, Community Bank and Mortgage. It has a 21.55 P/E ratio. It accepts various deposit products, including checking, savings, NOW, time deposit, and money market accounts, as well as certificates of deposit and other depository services.

Investors sentiment increased to 1.6 in 2017 Q4. Its up 0.55, from 1.05 in 2017Q3. It increased, as 7 investors sold Union Bankshares Corporation shares while 43 reduced holdings. 32 funds opened positions while 48 raised stakes. 30.13 million shares or 7.38% more from 28.06 million shares in 2017Q3 were reported. Price T Rowe Assoc Inc Md reported 533,527 shares or 0% of all its holdings. The Virginia-based Thompson Siegel Walmsley Ltd Liability Corporation has invested 0% in Union Bankshares Corporation (NASDAQ:UBSH). Virtu Llc has 0.01% invested in Union Bankshares Corporation (NASDAQ:UBSH) for 5,549 shares. Matarin Management Limited Liability Corp reported 20,867 shares. Ameritas Inv Prns Inc has 3,789 shares. First Mercantile Tru accumulated 2,710 shares. Martin And Company Tn stated it has 1% of its portfolio in Union Bankshares Corporation (NASDAQ:UBSH). Phocas Financial invested 0.45% of its portfolio in Union Bankshares Corporation (NASDAQ:UBSH). Bnp Paribas Arbitrage reported 13,777 shares. 78,615 are held by First Trust Advsr Ltd Partnership. Qs Limited Liability Corp accumulated 38,993 shares or 0.01% of the stock. Swiss Bancorp accumulated 0% or 74,458 shares. Parallax Volatility Advisers L P holds 6,678 shares or 0% of its portfolio. Carroll Associate has 33,996 shares. Credit Suisse Ag reported 57,689 shares or 0% of all its holdings.

Union Bankshares Corporation (NASDAQ:UBSH) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *